NSE · PGHL
Procter & Gamble Health Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹14,07,97,00,000 Cr with net profit ₹3,26,91,00,000 Cr — a 23.22% net margin, versus 24.82% the period before.
Shareholding
As of 2026-09-30
- Promoter51.82%
- Public29.13%
- FII6.42%
- DII12.63%
50,426 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.48× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #4 of 15 by market cap · medians across 14 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Alivus Life Sciences Ltd. | ₹15,354 Cr | 24.7 | 4.6 | 16.94% | 23.28% |
| Astrazeneca Pharma India Ltd. | ₹14,971 Cr | 86.3 | 17.15 | 21.49% | 6.97% |
| Akums Drugs & Pharmaceuticals Ltd. | ₹10,530 Cr | 34.48 | 3.17 | 7.7% | 6.48% |
| Procter & Gamble Health Limited(this company) | ₹8,325 Cr | 24.98 | 15.93 | 62.32% | 24.91% |
| Gujarat Themis Biosyn Ltd. | ₹4,217 Cr | 90.25 | 5.62 | — | 25.04% |
| Jagsonpal Pharmaceuticals Ltd. | ₹1,397 Cr | 29.7 | 5.09 | 15.6% | 15.47% |
| Bajaj HealthCare Limited | ₹1,052 Cr | 18.08 | 1.89 | 10.45% | 3.14% |
| Bafna Pharmaceuticals Ltd. | ₹1,048 Cr | 134.64 | 11.07 | 11.54% | 5.46% |
| Anuh Pharma Limited | ₹768 Cr | 17.38 | 2.19 | 11.65% | 5.67% |
| Amanta Healthcare Limited | ₹633 Cr | 41.28 | 2.88 | 7.46% | 5.04% |
AI analysis
AI-generated · google/gemini-2.5-flashProcter & Gamble Health Limited is listed on the Indian markets with a market capitalization of Rs 11,375 Cr. The company's PE ratio is 120.24 and its EPS is 196.94. The dividend yield stands at 6.06%.
Positives
- +The debt-to-equity ratio is very low at 0.02.
- +The Return on Equity (ROE) is high at 62.32%.
- +Return on Capital Employed (ROCE) is high at 71.75%.
- +The company reported a high dividend yield of 6.06%.
- +The latest reported annual profit margin is 23.22%.
Negatives
- −The number of shareholders decreased from 33,908 in Sep 2016 to 28,615 in Jun 2018.
- −The revenue decreased from Rs 1248.01 Cr in Jun 2023 to Rs 1166.89 Cr in Jun 2024.
- −The net profit decreased from Rs 229.47 Cr in Jun 2023 to Rs 200.98 Cr in Jun 2024.
Financial performance
In the latest reported annual period for Mar 2026, Procter & Gamble Health Limited reported revenue of Rs 1407.97 Cr and a net profit of Rs 326.91 Cr. The profit margin was 23.22%. Quarterly results for Mar 2026 show revenue of Rs 370.45 Cr and a net profit of Rs 94.6 Cr.
Profitability & returns
The company's Return on Equity (ROE) is 62.32% and Return on Capital Employed (ROCE) is 71.75%. The net profit margin for the latest reported period is 23.22%.
Balance sheet
Procter & Gamble Health Limited maintains a low debt-to-equity ratio of 0.02, indicating a minimal reliance on debt financing. The book value per share is Rs 316.01.
Ownership & pledges
There are no promoter share pledges reported.
Data as of — price: 2026-10-26 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Procter & Gamble Health Limitedshare price & fundamentals